Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind phase 2 trial of an octavalent HPV L1 VLP vaccine versus quadrivalent GARDASIL
2006-004933-14Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of octavalent HPV L1 VLP vaccine in human papillomavirus infection, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN) and 4 more (2 arms), sponsored by Merck & Co. Primary endpoint: Primary efficacy endpoint: persistent infection or related disease due to HPV 31, 45, 52, or 58. Started Nov 2006; status: terminated.
02
Drugs
octavalent HPV L1 VLP vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)Vulval carcinomavulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2006-004933-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004933-14.